School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
Department of Basic Pharmaceutical Sciences, School of Pharmacy, Husson University, Bangor, ME, USA.
Eur J Pharm Biopharm. 2017 Oct;119:381-395. doi: 10.1016/j.ejpb.2017.07.010. Epub 2017 Jul 21.
Extracellular vesicles (EVs) are intrinsic mediators of intercellular communication in our body, allowing functional transfer of biomolecules (lipids, proteins, and nucleic acid) between diverse locations. Such an instrumental role evokes a surge of interest within the drug delivery community in tailoring EVs for therapeutic delivery. These vesicles represent a novel generation of drug delivery systems, providing high delivery efficiency, intrinsic targeting properties, and low immunogenicity. In the recent years, considerable research efforts have been directed toward developing safe and efficient EV-based delivery vehicles. Although EVs are shown to harbor great promise in therapeutic delivery, substantial improvements in exploring standardized isolation techniques with high efficiency and robust yield, scalable production, standard procedures for EV storage, efficient loading methods without damaging EV integrity, understanding their in vivo trafficking, and developing novel EV-based nanocarriers are still required before their clinical transformation. In this review, we seek to summarize the recent advance on harnessing EVs for drug delivery with focus on state-of-the-art solutions for overcoming major challenges.
细胞外囊泡(EVs)是体内细胞间通讯的固有介质,允许生物分子(脂质、蛋白质和核酸)在不同位置之间进行功能转移。这种关键作用在药物输送领域引发了人们对定制 EV 进行治疗性输送的浓厚兴趣。这些囊泡代表了新一代药物输送系统,具有高效的输送效率、内在的靶向特性和低免疫原性。近年来,人们投入了大量的研究努力来开发安全有效的 EV 基输送载体。尽管 EV 显示出在治疗性输送方面具有巨大的潜力,但仍需要在标准化的分离技术方面取得实质性的改进,以提高效率和稳健的产量、可扩展的生产、EV 储存的标准程序、在不破坏 EV 完整性的情况下进行有效加载的方法、了解它们的体内迁移,并开发新型基于 EV 的纳米载体,然后才能将其转化为临床应用。在这篇综述中,我们旨在总结利用 EV 进行药物输送的最新进展,重点介绍克服主要挑战的最新解决方案。